New insider activity at Idexx Laboratories ( (IDXX) ) has taken place on August 12, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sharon Underberg, the Executive Vice President, General Counsel, and Corporate Secretary of Idexx Laboratories, recently executed a significant transaction by selling 5,450 shares of the company’s stock. This sale amounted to a total value of $3,551,220, highlighting a noteworthy financial move within the company’s executive team.
Recent Updates on IDXX stock
Idexx Laboratories recently reported strong financial results for Q2 2025, with an 11% revenue growth and a 9% organic growth, driven by the Companion Animal Group and Water segments. The company achieved a 17% increase in earnings per share, reaching $3.63, supported by strategic innovations and strong commercial execution. Record instrument placements and international expansion contributed significantly to this performance. Despite challenges in the U.S. market, such as a decline in clinical visits and rapid assay revenues, Idexx raised its full-year revenue and EPS guidance, reflecting confidence in continued growth. Analysts raised price targets due to these robust earnings, strategic focus on innovation, and successful international expansion.
Spark’s Take on IDXX Stock
According to Spark, TipRanks’ AI Analyst, IDXX is a Outperform.
Idexx Laboratories demonstrates strong financial performance and positive earnings call sentiment, driving a high overall score. Technical indicators support a bullish outlook, although the high P/E ratio suggests the stock is expensive. The company’s strategic focus on international markets and innovation positions it well for future growth.
To see Spark’s full report on IDXX stock, click here.
More about Idexx Laboratories
YTD Price Performance: 59.50%
Average Trading Volume: 604,611
Technical Sentiment Signal: Buy
Current Market Cap: $52.17B